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Objectives: To describe the variability in renal function markers in non-azotaemic and 
azotaemic cats and also the rate of change in the markers. 
Methods:  Plasma creatinine concentration and its reciprocal, glomerular filtration rate 
(GFR) and urine specific gravity (USG) were studied as markers of renal function in 
client owned cats. GFR was determined using a corrected slope-intercept iohexol 
clearance method. Renal function testing was performed at baseline and a second time 
point. The within-population variability (coefficient of variation; CV%) was determined 
at the baseline time-point. Within-individual variability (CV%) and rate of change over 
time was determined from the repeated measurements. 
Results: Twenty-nine cats were included in the study of which five had azotaemic 
chronic kidney disease. The within-individual variability (CV%) in creatinine 
concentration was lower in azotaemic cats compared to non-azotaemic cats (6.81% vs. 
8.82%) whereas, the within-individual variability in GFR was higher in azotaemic cats 
(28.94% vs. 19.98%). The within-population variability was greatest for USG (67.86% 
in azotaemic cats and 38.00% in non-azotaemic cats). There was a negative rate of 
change in creatinine concentration in azotaemic and non-azotaemic cats (-0.0265 and -
0.0344 µmol/l/day respectively) and a positive rate of change of GFR in azotaemic and 
non-azotaemic cats (0.0062 and 0.0028 ml/min/day respectively). 
Conclusions and relevance: The within-individual variability data suggests creatinine 
concentration to be the more useful marker for serial monitoring of renal function in 
azotaemic cats. In contrast, in non-azotaemic cats, GFR is a more useful marker for 
serial monitoring of renal function. The majority of cats with azotaemic CKD did not 
have an appreciable decline in renal function during the study.  
 
Introduction 
Important clinical applications of renal function testing include early detection 
of renal dysfunction and monitoring for progressive disease. Plasma or serum creatinine 
concentration is the most widely used renal function test in veterinary clinical practice 
and is a surrogate marker of glomerular filtration rate (GFR). There exists an 
exponential relationship between creatinine and GFR so that in early chronic kidney 
disease (CKD) there can be large changes in GFR with relatively small changes in 
creatinine concentration.1 Therefore, creatinine is considered insensitive for detecting 
early CKD. In addition, factors other than GFR can influence creatinine concentration, 
most notably muscle mass. Reference intervals determined by individual laboratories 
for creatinine are variable.2 This can lead to misclassification of patients as normal or 
abnormal depending on the laboratory to which the sample is submitted.2  
GFR is considered the most sensitive and accurate measurement of functioning 
renal mass. Limited3 and single4 sampling plasma clearance techniques have been 
validated for cats facilitating measurement of GFR and making it practical and 
accessible for patients in clinical practice. However, reference intervals remain poorly 
defined. 
It is recognized that better methods for early detection of CKD are required for 
cats. Considering the limitations of using reference intervals and specific cut-offs to 
define if a patient has normal or abnormal renal function and the insensitivity of single 
measurements of creatinine for early kidney disease, repeated measurements in which 
each patient serves as its own control may provide more clinically useful information 
when evaluating change in renal function. This requires knowledge of the normal 
variability in measurement between two time points. It also allows more dynamic rather 
than static assessment of renal function. Furthermore, an increase in creatinine 
concentration or decrease in GFR greater than the expected variability in cats with 
stable CKD, may suggest more progressive CKD and prompt the clinician to change the 
management plan or monitor the cat more closely. 
The study objectives were twofold; firstly, to describe the variability in serum creatinine 
concentration, GFR and USG as markers of renal function in non-azotaemic and 
azotaemic patients and secondarily to describe the rate of change in the markers. 
 
Materials and methods 
Study population 
Client-owned senior cats (>9 years) with varying renal function were identified through 
a senior cat wellness screening programme that was conducted at a London-based first 
opinion practice (Beaumont Sainsbury Animals’ Hospital, Royal Veterinary College). 
Cats with evidence of concurrent medical disease such as hyperthyroidism were 
excluded. Informed consent was obtained from the owners and the study was conducted 
with approval from the Royal Veterinary College’s Ethics and Welfare committee.  
Measurement of renal function markers 
GFR was determined using a previously described slope-intercept iohexol clearance 
method.3 Briefly, a bolus dose of iohexol (OmnipaqueTM [647mg/ml; 300mg of 
iodine/ml]) was administered intravenously (1ml/kg). Blood samples were collected at 
120, 180 and 240 min post-injection. Iohexol concentrations were determined at an 
external commercial laboratory using a HPLC methodi. Clearance was determined as 
dose/AUC where AUC is area under the plasma concentration versus time curve 
determined using a one-compartment model. A previously validated cat specific 
correction formula for slope-intercept clearance was applied to correct for the one 
compartment assumption.3 In addition, creatinine concentrations were determined from 
a sample collected at the same time as GFR measurement. USG was determined from a 
urine sample collected by cystocentesis prior to the administration of iohexol. For 
statistical analysis, one was subtracted from USG. 
Renal function testing, as described above, was performed at baseline and repeated 
approximately 6 months after the initial measurement. Measurements were therefore 
performed at two time-points in each cat. 
Cats were classified as having azotaemic CKD if they had a persistently increased 
plasma creatinine concentration above the laboratory reference interval (> 2.0 mg/dl 
[177 µmol/l]) in association with decreased urine concentrating ability (USG < 1.035). 
Non-azotaemic cats did not receive any drugs or diet that might influence GFR during 
the study period. Azotaemic cats did not receive any drugs that may influence GFR, 
however, renal diet was offered to all azotaemic cats, the intake of which was variable.  
 
Data analysis 
Descriptive statistics only were performed due to the small numbers of cats included in 
the study and the high variability between cats that would limit the statistical power if 
performing inferential statistics. 
Percent variation (CV;%) was calculated as (standard deviation [SD]/mean) x 100.  Rate 
of change over time was calculated as (measurement time-point 2 – measurement time-
point 1)/ number of days between measurements. GFR unscaled to body weight (i.e. 
ml/min) was also included to ensure variations in weight were not influencing variation 
in GFR. Units for rate of change of the reciprocal of creatinine were converted to 
l/mmol/day. 
 
Results 
There were a total of 29 cats included in the study. Five of these cats had azotaemic 
CKD. The median (range) age was 12.1 (7.8 – 19.0) years. Of the 29 cats, 14 were 
female neutered and 15 were male neutered. Twenty cats were DSH/DLH and nine cats 
were pedigree (two Burmese, two Russian blue, two Persian, British short hair, Bengal 
and Ocicat). Repeated measurements of GFR were performed a mean number of 234 
days following initial measurement. The within-population variability (CV%) for 
creatinine concentration, reciprocal of creatinine, USG and GFR was greater in both 
azotaemic and non-azotaemic cats compared to the within-individual variation (see 
Table 1) except for non-standardised GFR in azotaemic cats. Azotaemic cats had lower 
within-individual variability for creatinine concentration (6.81 vs 8.82%; see Table 1) 
and USG (13.19% vs 26.66%; see Table 1) compared to non-azotaemic cats. The 
within-individual variability in GFR was higher in azotaemic versus non-azotaemic cats 
(28.94% vs 19.98%). The mean within-individual body weight in azotaemic and non-
azotaemic cats was 4.62kg and 4.25kg respectively and the mean within-individual 
variability 4.65% and 5.44% respectively.  
 
The rate of change of creatinine concentration was negative in both azotaemic (-0.0265 
µmol/l/day; see Table 2) and non-azotaemic cats (-0.0344 µmol/l/day). There was a 
positive rate of change of GFR in both azotaemic and non-azotaemic cats (0.0062 
ml/min/day and 0.0028 ml/min/day respectively). The mean ± SD rate of change of 
BW in azotaemic and non-azotaemic cats was 0.0009 ± 0.0008kg and -0.0005 ± 
0.0017kg. 
 
Discussion 
Repeated measurements of renal function were performed in cats with varying renal 
function to investigate within-individual variability and changes in kidney function over 
time. The within-population variability in renal function markers is larger when 
compared to the within-individual variation. Therefore serial monitoring of renal 
markers in which each cat serves as its own baseline may prove to be more useful in the 
earlier detection of disease than evaluating a single static measurement using a defined 
cut-off with a dichotomous diagnosis (does the cat have or not have azotaemia). 
The within-individual variability (CV%) in creatinine concentration was lower in 
azotaemic cats compared to non-azotaemic cats (6.81% vs 8.82%) whereas, the within-
individual variability in GFR was higher in azotaemic cats (28.94% vs 19.98%). These 
values were similar to those reported in human patients with normal renal function in 
which the within-individual variation in creatinine concentration was 5.8% and GFR 
was 18.7%.5 The results of the present study suggest that if performing serial 
monitoring in a patient that is azotaemic, creatinine may be the more useful marker as 
normal within-individual variability is lower and an increase in concentration is more 
likely to be clinically significant. In contrast, there is lower within-individual variability 
in GFR in non-azotaemic cats and a decline in GFR is more likely to be clinically 
significant. Considering the exponential relationship between creatinine concentration 
and GFR it is apparent that in early stages of disease there are large decreases in GFR 
with a correspondingly small increases in creatinine concentration but in later stages of 
disease, when the change in GFR is smaller, the increase in creatinine concentration is 
greater. This would also support the use of creatinine as a monitoring tool for patients 
with abnormal renal function and GFR as monitoring tool for patients with normal or 
borderline renal function. The reason as to the greater within-individual variability in 
GFR in azotaemic patients in unclear. GFR is biologically more variable due to the 
influence of renal haemodynamics and fluid volume status whereas the production of 
endogenous creatinine is relatively constant. The within-individual variability in GFR 
does suggest that in cats with azotaemic CKD, there still remains functional renal 
reserve. However, the influence of feeding a renal diet, or greater response to 
haemodynamic change cannot be completely excluded. All of the azotaemic cats in the 
present study were in IRIS stage 2 and 3 and none of the cats were in advanced stage 
(IRIS stage 4) CKD. It has been shown in cats with surgically induced models of kidney 
disease that following partial nephrectomy, the kidneys undergo renal hypertrophy and 
that this correlates with an increase in single nephron GFR.6, 7 It is possible that the cats 
included in the study also underwent similar renal hypertrophy. Renal biopsies were not 
performed to explore this hypothesis further. It is possible that some of the variability in 
GFR could reflect poor assay repeatability, however, it is reported that the 
methodological imprecision associated with iohexol analysis is minor compared to 
biological variation in GFR.8  
A further finding of interest in the present study is the positive slope for the rate of 
change of GFR in both azotaemic and non-azotaemic cats. This supports the suggestion 
that azotaemic cats do indeed have sufficient functional renal reserve to increase their 
GFR.  This may be the result of hyperfiltration of remaining nephrons which is a 
presumed maladaptive process contributing to progressive CKD, however, further 
studies would be required to investigate this. There was a corresponding decrease in 
creatinine concentration in azotaemic cats over time. One may assume this is due to 
increased renal clearance of creatinine. It is possible that decreased endogenous 
production of creatinine due to reduced muscle mass in azotaemic cats may also 
contribute to a reduced creatinine concentration over time, however, the positive rate of 
change in body weight would not support this. 
The within-population variation in USG was high in all cats but particularly in 
azotaemic cats (67.86% in azotaemic cats vs 38.00% in non-azotaemic cats). This most 
likely reflects the influence of non-renal factors such as water intake or diet on USG and 
highlights the limitations of using a single static urine sample in interpretation of renal 
function. USG can range from 1.001 to 1.080 in cats with normal renal function and 
cats that have undergone surgical ablation of the kidneys have been shown to retain 
significant urine concentrating ability. The within-individual variability in USG 
(13.19% in azotaemic cats and 26.66% in non-azotaemic cats) was lower than the 
within-population suggesting that serial monitoring of USG may prove more useful in 
detecting change in renal function compared to a single static measurement. USG is a 
simple clinical measurement that can be obtained from a urine sample perhaps collected 
by an owner at home and further longitudinal studies evaluating this marker would be 
an area for future study. A single USG measurement at baseline has not been found to 
predict the development of azotaemic CKD in cats within a 12-month follow up period.9 
However, rate of change has not been studied. 
The reciprocal of creatinine has been suggested to be a useful marker of progression of 
kidney disease. Serial measurement of GFR and the reciprocal of creatinine in canine 
remnant kidney models found poor correlation.6 In the present study, the correlation 
between rate of change of the reciprocal of creatinine and GFR in cats was not 
significant in either azotaemic (r = -0.24, P = 0.695) or non-azotaemic (r = 0.21, P = 
0.334) cats.  
Longitudinal measurements in human patients with early CKD identified a severe 
decrease in eGFR (>4ml/min/year) in 24%, moderate decrease in eGFR (1-
4ml/min/year) in 28%, mild decrease in eGFR (0-1ml/min/year) in 10% and no decrease 
in eGFR in 38% of patients.12 In the present study, there were only a small number of 
cats included with azotaemic CKD (n=5) and of these cats only 1/5 (20%) had a 
decrease in GFR over time. It is possible that the remaining azotaemic cats belonged to 
a subset of diseased population in which there is no progressive decline in renal 
function or it may be that the repeated measurements were performed over an 
insufficient time period. A recent study that assessed renal function over a 6 month 
follow-up period also reported that in the dogs with IRIS stage 2 CKD, there was no 
change in GFR.13 
The wide use of electronic clinical record systems in the majority of veterinary practices 
may facilitate monitoring of serial measurements of creatinine and/or GFR in clinical 
patients. Rate of decline of renal function could be incorporated into IRIS guidelines to 
help classify patients with early stage CKD or progressive disease. Furthermore, an 
increase in creatinine concentration variability (CV%) above that considered to be 
normal within-individual variation (e.g. 6.81% in azotaemic cats and 8.82% in non-
azotaemic cats) could be bought to the attention of the clinician prompting closer 
monitoring or a change in management for the patient.  
It remains unclear how many cats with early stage CKD have intrinsic kidney damage 
that is likely to progress. Furthermore, there are no studies examining renal pathology in 
these early stages of naturally occurring disease. The fibrotic and inflammatory changes 
typically reported in cats with chronic kidney disease likely just reflect a chronic and 
irreversible disease process associated with late stage disease. By monitoring serial 
measurements and observing an increase in creatinine concentration or decrease in GFR 
above the expected norm suggesting declining renal function and potential on-going 
intrinsic renal damage, would be a strong argument for performing renal biopsy. This 
could provide valuable information regarding pathophysiology of disease. 
There are a number of limitations to the present study not least the small number of cats 
particularly those with azotaemic CKD that were included.  Only two repeated 
measurements were performed with a mean 234 day interval. This may not be a 
sufficient number of samples to detect a clinically significant measure of the rate of 
change in an individual patient and further longitudinal studies with additional 
measurements over a longer time course could provide further information. A further 
limitation is that the population of cats studied mainly included older cats. However, 
given that this is the population in which CKD is most commonly recognised and often 
present the greatest diagnostic challenge, the findings were considered to be 
representative. In addition, the findings of the study cannot be extrapolated to cats with 
concurrent disease such as hyperthyroidism that may itself affect renal function, as cats 
with concurrent disease were excluded.  
 
Conclusions 
The within-individual variability in creatinine concentration is lower in azotaemic cats 
compared to non-azotaemic cats which, coupled with the insensitivity of creatinine as a 
marker of early renal dysfunction, suggests it is a more useful marker for serial 
monitoring of renal function in azotaemic cats. In contrast, the within-individual 
variability in GFR is lower in non-azotaemic cats and its sensitivity as a marker of early 
renal dysfunction suggests it is a more useful marker for serial monitoring of renal 
function in non-azotaemic cats. The majority of cats with azotaemic CKD included in 
the study did not have a decline in renal function defined by decreasing GFR which may 
suggest that there was sufficient adaptation of remaining functioning nephrons to 
increase GFR over the time period studied. 
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Table 1: Within-population and within-individual mean, SD and CV for creatinine and reciprocal of 
creatinine concentration, USG, and GFR in azotaemic and non-azotaemic cats. 
  Mean within-
population 
(baseline) 
SD within-
population 
(baseline) 
CV within-
population 
(baseline) 
Mean within-
individual 
Mean SD 
within-
individual 
Mean CV 
within-
individual 
Creatinine 
(µmol/l) 
All cats 153.96 55.33 35.94% 150.79 12.29 8.47% 
Azotaemic cats 247.80 58.10 23.45% 244.22 15.81 6.81% 
Non-azotaemic 
cats 
134.40 28.75 21.39% 131.32 11.55 8.82% 
Reciprocal 
creatinine 
(l/µmol) 
All cats 0.007 0.002 28.57% 0.007 0.001 8.47% 
Azotaemic cats 0.004 0.001 25.00% 0.004 <0.001 6.81% 
Non-azotaemic 0.008 0.002 25.00% 0.008 0.001 8.82% 
cats 
USG All cats 0.046 0.020 43.48% 0.042 0.011 23.85% 
Azotaemic cats 0.028 0.019 67.86% 0.025 0.004 13.19% 
Non-azotaemic 
cats 
0.050 0.019 38.00% 0.047 0.012 26.66% 
GFR 
(ml/min/kg) 
All cats 1.63 0.63 38.65% 7.91 1.64 21.53% 
Azotaemic cats 0.84 0.37 44.05% 4.39 1.35 28.94% 
Non-azotaemic 
cats 
1.80 0.54 30.00% 8.64 1.70 19.98% 
GFR 
(ml/min) 
All cats 6.80 2.73 40.15% 7.13 1.28 19.01% 
Azotaemic cats 3.51 0.79 22.51% 4.22 1.20 27.03% 
Non-azotaemic 
cats 
7.49 2.48 33.11% 7.74 1.31 17.33% 
 
Table 2: Rate of change per day of creatinine and reciprocal of creatinine concentration, USG and GFR in 
azotaemic and non-azotaemic cats. 
 Rate of change 
Mean SD 
Creatinine 
(µmol/l/day) 
All cats -0.0331 0.1135 
Azotaemic cats -0.0265 0.1065 
Non-azotaemic cats -0.0344 0.1171 
Reciprocal All cats 0.0014 0.0062 
creatinine 
(l/mmol/day) 
Azotaemic cats 0.004 0.0023 
Non-azotaemic cats 0.0016 0.0068 
USG (USG/day) 
All cats <-0.0001 0.0001 
Azotaemic cats <-0.0001 <0.0001 
Non-azotaemic cats <-0.0001 0.0001 
GFR (ml/min/day) 
All cats 0.0034 0.0105 
Azotaemic cats 0.0062 0.0060 
Non-azotaemic cats 0.0028 0.0113 
 
 
 
